Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Inflammation gene variants and susceptibility to albuminuria in the U.S. population: analysis in the Third National Health and Nutrition Examination Survey (NHANES III), 1991-1994

  • Renée M Ned1Email author,
  • Ajay Yesupriya1,
  • Giuseppina Imperatore2,
  • Diane T Smelser1, 3,
  • Ramal Moonesinghe4,
  • Man-huei Chang1 and
  • Nicole F Dowling1
BMC Medical Genetics201011:155

DOI: 10.1186/1471-2350-11-155

Received: 15 April 2010

Accepted: 5 November 2010

Published: 5 November 2010

Abstract

Background

Albuminuria, a common marker of kidney damage, serves as an important predictive factor for the progression of kidney disease and for the development of cardiovascular disease. While the underlying etiology is unclear, chronic, low-grade inflammation is a suspected key factor. Genetic variants within genes involved in inflammatory processes may, therefore, contribute to the development of albuminuria.

Methods

We evaluated 60 polymorphisms within 27 inflammatory response genes in participants from the second phase (1991-1994) of the Third National Health and Nutrition Examination Survey (NHANES III), a population-based and nationally representative survey of the United States. Albuminuria was evaluated as logarithm-transformed albumin-to-creatinine ratio (ACR), as ACR ≥ 30 mg/g, and as ACR above sex-specific thresholds. Multivariable linear regression and haplotype trend analyses were conducted to test for genetic associations in 5321 participants aged 20 years or older. Differences in allele and genotype distributions among non-Hispanic whites, non-Hispanic blacks, and Mexican Americans were tested in additive and codominant genetic models.

Results

Variants in several genes were found to be marginally associated (uncorrected P value < 0.05) with log(ACR) in at least one race/ethnic group, but none remained significant in crude or fully-adjusted models when correcting for the false-discovery rate (FDR). In analyses of sex-specific albuminuria, IL1B (rs1143623) among Mexican Americans remained significantly associated with increased odds, while IL1B (rs1143623), CRP (rs1800947) and NOS3 (rs2070744) were significantly associated with ACR ≥ 30 mg/g in this population (additive models, FDR-P < 0.05). In contrast, no variants were found to be associated with albuminuria among non-Hispanic blacks after adjustment for multiple testing. The only variant among non-Hispanic whites significantly associated with any outcome was TNF rs1800750, which failed the test for Hardy-Weinberg proportions in this population. Haplotypes within MBL2, CRP, ADRB2, IL4R, NOS3, and VDR were significantly associated (FDR-P < 0.05) with log(ACR) or albuminuria in at least one race/ethnic group.

Conclusions

Our findings suggest a small role for genetic variation within inflammation-related genes to the susceptibility to albuminuria. Additional studies are needed to further assess whether genetic variation in these, and untested, inflammation genes alter the susceptibility to kidney damage.

Background

Persistent kidney damage is a defining criterion for chronic kidney disease, a condition that exists in at least 12% of adults in the United States using data from 1999-2004 [1, 2]. The presence of kidney damage is often indicated by increased urine albumin, which is present in approximately 9-14% of the adult U.S. population [1, 2]. Albuminuria serves not just as an important marker of kidney damage but also as a prognostic factor for the progression of kidney disease. In fact, kidney damage often precedes a decline in normal kidney function. Of great clinical importance, albuminuria is also a strong and independent predictor of cardiovascular disease (CVD), and of all-cause and CVD-related mortality (reviewed in [3, 4]), even at levels conventionally considered within the normal range [5].

In adults, the prevalence of albuminuria rises with age and is further increased in the presence of hypertension or diabetes. In the U.S. population, the estimated prevalence of microalbuminuria (typically defined as urinary albumin-to-creatinine ratio (ACR) between 30 and 299 mg/g) is approximately 3% in adults without adverse health conditions, but is approximately 17% in hypertensive persons and approximately 29% in those with diabetes [6].

The underlying cause(s) of albuminuria are numerous; but, the mechanisms of injury that lead to loss of albumin in the kidneys are unclear. However, some data suggest that albuminuria is a consequence of widespread vascular endothelial dysfunction or of chronic, low-grade inflammation [7, 8], two pathophysiologic processes that may also underlie the strong link between albuminuria and cardiovascular disease. These processes are themselves tightly linked, as inflammation has been shown to be a major determinant, and consequence, of endothelial dysfunction [9, 10]. Since cytokines and other molecules that mediate inflammation can mediate vascular damage, they may play an important role in the pathogenesis of kidney damage. However, most studies that have found an association between albuminuria and various serum or plasma markers of inflammation (e.g., CRP, IL-6, TNF-α, fibrinogen, white blood cell count) have been cross-sectional [1116]; therefore, no determination of temporality or causality could be made. Prospective studies have found that the development of increased urinary albumin excretion is preceded by elevated levels of inflammation markers: CRP in a general white population [17] and both CRP and fibrinogen in persons with type 2 diabetes [18]. Such studies lend support to the notion that inflammation may contribute to the development of kidney damage.

Accordingly, we were interested in testing genetic associations with albuminuria for genes involved in the inflammatory response. There have been few such studies to date, with the majority of analyses having tested for association specifically with diabetic nephropathy, end-stage renal disease, or with morbidity or mortality in these patient populations [1922], but not with albuminuria or other measures of kidney damage. Therefore, the goal of this study was to assess the genetic contribution to the development of albuminuria by testing polymorphisms in 27 genes involved in the inflammatory response in DNA samples collected from participants in the Third National Health and Nutrition Examination Survey (NHANES III). This work is the first to examine the association of genetic polymorphisms with albuminuria using a population-based, nationally representative sample of the U.S. population.

Methods

Study population

NHANES III is a population-based and nationally representative survey of the civilian, noninstitutionalized population of the United States aged 2 months or older that was conducted from 1988-1994 by the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention (CDC) [23, 24]. The survey relied on a multistage, complex survey design that included four self-identified race/ethnic groups: non-Hispanic white, non-Hispanic black, Mexican American, and "other." Oversampling in certain populations-- the very young, the elderly, non-Hispanic blacks, and Mexican Americans--was performed in order to produce more unbiased estimates of disease prevalence and other health indicators in these groups [25]. During the second phase of NHANES III (1991-1994), white blood cells were frozen and cell lines immortalized with Epstein-Barr virus, creating a DNA bank [25]. This DNA bank contains specimens from 7159 participants aged 12 years or older [26], whose characteristics have been described [27].

Analyses were limited to DNA samples of participants aged 20 years or older (N = 5948) since normal values for albumin excretion in children are not well established and the assessment of proteinuria in children differs from adults [28, 29]. The following persons were then excluded: pregnant women (N = 111), persons in the "other" race/ethnic group (N = 276), and individuals with a self-reported history of kidney cancer (N = 7). We also excluded menstruating women (N = 233), as others have done [1, 6, 30], after finding elevated urine albumin excretion in this group (data not shown). The final sample size included 5321 adult participants: 2249 non-Hispanic whites, 1502 non-Hispanic blacks, and 1570 Mexican Americans.

Selection of genes and polymorphisms

Specific genes were included in our analysis based on their involvement in inflammation as determined by information gathered from GeneCards [31], Gene Ontology [32, 33], and the published literature in the case of VDR [34]. All available variants within these genes were included in the current study without regard to allele frequency or the amount of linkage disequilibrium between variants. The majority of the polymorphisms were chosen from a larger set that had been genotyped for an NHANES III study on allele frequencies and genotype prevalence in the U.S. population [27]. In addition, the two available variants from relevant genome-wide association studies were also included: GCKR variant rs1260326 in relation to plasma C-reactive protein levels [35]; and rs890945 in an unknown gene in relation to kidney function [36].

Genotyping and quality control methods

Polymorphisms in APOE (N = 2), CRP (N = 15), GCKR (N = 1), and an unknown gene (N = 1) were genotyped in NHANES III by various investigators [26]. Our group genotyped all remaining variants included in this study; and details have been published [27]. Briefly, rs890945 and eight CRP variants (rs35500644, rs11265260, rs12093699, rs12744244, rs2027471, rs2592887, rs2794520, and rs3093075) were genotyped by a custom Illumina GoldenGate assay (San Diego, CA). GCKR variant rs1260326 was genotyped on a matrix-assisted laser-desorption ionization time-of-flight mass spectroscopy platform (Sequenom, San Diego, CA) [37]. All remaining polymorphisms were genotyped using TaqMan (Applied Biosystems, Foster City, CA) or MGB Eclipse (Nanogen, Bothell, WA) assays [27, 38, 39]. Genotyping was performed by laboratory staff that were blinded to the phenotypic data of the study participants. All genetic variants passed quality control criteria as defined by NCHS [26, 27].

Measurements and definitions

Urinary albumin (μg/mL) and urinary creatinine (mg/dL) were measured from one random, untimed spot urine collection as previously described [6]. Urinary albumin concentration was measured by solid-phase fluorescent immunoassay; and urinary creatinine concentration was measured by the modified kinetic Jaffe method. Further details of all NHANES III laboratory methods are available online [40]. Albuminuria was defined using the continuous variable urinary albumin-to-creatinine ratio (ACR) and as dichotomous variables using either a single threshold (urinary ACR ≥ 30 mg/g) or sex-specific cut-offs (urinary ACR ≥ 17 mg/g in men and ≥ 25 mg/g in women) to account for greater creatinine excretion in men than in women.

Several variables were used to characterize study participants and were included in multivariable-adjusted analyses. Age was categorized as 20-50 yrs or ≥ 50 yrs. Waist-to-hip ratio was defined by sex-specific cut-offs: 0.90 for males and 0.85 for females. Diabetes was defined as self-reported diabetes (answering "yes" to "ever been told you have sugar/diabetes"), but excluding women with a history of only gestational diabetes. Hypertension was defined as systolic blood pressure (bp) ≥ 140 mmHg, diastolic bp ≥ 90 mmHg, or if the participant was currently taking prescribed medicine for hypertension. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease Study equation re-expressed for use with a standardized serum creatinine (Scr) assay [4143]:

eGFR = 175 × (standardized Scr -1.154) × (age-0.203) × (0.742 if female) × (1.212 if black). NHANES III serum creatinine values were standardized as described [44].

Statistical analysis

All analyses were performed using SAS-Callable SUDAAN 10 (Research Triangle Institute, Research Triangle Park, NC, USA) and SAS 9.2 (SAS Institute, Cary, NC, USA) to account for the NHANES III complex sampling design. Nationally representative estimates were calculated using sample weights for the NHANES III DNA bank as previously described [27]. Appropriate standard errors and confidence intervals were calculated using the Taylor series linearization approach [45, 46] to correct for correlations within sampled clusters, including the possible genetic relatedness of persons sampled from the same household.

In descriptive analyses, the prevalence of albuminuria and the geometric mean of ACR were calculated by relevant demographic and clinical characteristics of the participants. Allele frequencies and tests for deviations from Hardy-Weinberg proportions were calculated as previously described [27]. The associations between the genetic variants and each outcome were assessed separately in each race/ethnic group in crude and adjusted logistic regression models. Associations were also examined in combined analyses of all participants after controlling for race/ethnicity in the logistic regression models. Urinary ACR was positively skewed and, thus, logarithm-transformed to approximate a normal distribution. The logarithm-transformed values were used in all analyses of urinary ACR as a continuous variable. Covariates were determined by significant association (P < 0.05) of the variable (i.e., age, sex, education, smoking, alcohol use, and waist-to-hip ratio) with the outcome in non-genetic models in at least one of the race/ethnic groups. Hypertension and diabetes were not considered, as these conditions are often part of the causal pathways that result in chronic kidney disease. Variables included in all multivariable models are listed in each table.

Genetic variants were tested assuming two modes of inheritance: additive (with a change in the odds ratio or beta-coefficient per copy of the minor allele) or codominant (all three genotypes assessed individually). The minor allele of each variant was defined by the prevalence in the total population using NHANES III genetic data [27, 39]. Haplotype trend regression [47] was used to test for associations involving multiple variants within a single gene. The HAPLOTYPE procedure available in SAS/Genetics 9.2 was used to calculate the probability that an individual has a specific haplotype given their unphased genotype and the estimated haplotype frequencies. Haplotype terms that reflected the number and probabilities of the haplotypes were defined based on the method proposed by Zaykin, et al. [47]. Since our study included a large number of polymorphisms in CRP, the incremental search algorithm available in the HTSNP procedure in SAS/Genetics 9.2 was used to identify a set of markers for this gene that tagged non-rare (frequency >5%) haplotypes with a proportion of diversity explained (PDE) greater than 0.99. The haplotype analysis for CRP included only those markers identified with this procedure: rs2027471, rs3091244, and rs12744244. Rare haplotypes (frequency < 5%) within each gene were coded in aggregate as "other", except in cases where only one haplotype was rare. The major isoforms of APOE -ε2, ε3, and ε4-were determined from the rs429358 and rs7412 variants as previously described [39] and were tested assuming additive and codominant modes of inheritance. For all genes, the effect of each individual haplotype, as well as the overall association between all haplotypes and each outcome, were tested using regression models. Regression models with CRP variant rs35500644 often produced errors in SUDAAN due to its very low minor allele frequency. This variant was, consequently, excluded from presentation and inclusion in any haplotypes.

Prevalence odds ratios and beta-coefficients with 95% confidence intervals were estimated from both univariate and multivariable regression models. All associations (descriptive and genetic) were tested at the threshold of 0.05 using the Satterthwaite-adjusted F-statistic, a stable and preferred test statistic for the analysis of complex survey data [48]. For all genetic association analyses, P-values from the Satterthwaite-adjusted F-statistics were adjusted to control for the false discovery rate (FDR) [49, 50] in each race/ethnic group.

Results

Basic demographic characteristics and urinary albumin excretion profile of the included NHANES III participants (N = 5321) are listed in Table 1. The geometric mean of ACR differed among most measured demographic and clinical groups, including those defined by sex, age, and waist:hip ratio (P value ≤ 0.0007 for all). However, this measurement did not differ by race/ethnic group or by smoking status. The estimated total population prevalence of albuminuria in adults ≥ 20 years was 10.98 ± 0.80%, with approximately 9.8% of men and 12.2% of women having the condition as defined by sex-specific cutoff values. The prevalence of albuminuria was considerably higher in older participants, in persons with diabetes, and in persons with hypertension (all P <0.0001). The prevalence of albuminuria also differed by race/ethnic group, educational attainment, alcohol use, and waist:hip ratio. In participants with elevated levels of serum CRP, which is a common indicator of inflammation, the geometric mean of ACR and the prevalence of albuminuria were increased (P < 0.0001). Participants with moderately to severely reduced kidney function, defined as estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2, also displayed a higher prevalence of albuminuria and elevated geometric mean of ACR (P < 0.0001).
Table 1

Characteristics of included study participants (≥ 20 years old), NHANES III DNA bank, 1991-1994

   

ACR

Albuminuriab

Characteristic

Unweighted sample size

(N)

Weighted frequency

(%a)

Geometric mean (mg/g) ± SE

P-value

Prevalence (%a) ± SD

P-value

Gender

      

   Female

2884

49.38

6.40 ± 0.33

< 0.0001

12.15 ± 1.12

0.1548

   Male

2437

50.62

4.28 ± 0.28

 

9.84 ± 1.10

 

Age (years)

      

   20-50

3018

62.75

3.93 ± 0.20

< 0.0001

5.04 ± 0.62

< 0.0001

   ≥ 50

2303

37.25

8.48 ± 0.45

 

21.10 ± 1.41

 

Race/ethnicity

      

   Non-Hispanic white

2249

82.35

5.32 ± 0.30

0.1486

10.44 ± 0.89

0.0021

   Non-Hispanic black

1502

11.96

4.95 ± 0.28

 

14.99 ± 1.11

 

   Mexican-American

1570

5.69

4.50 ± 0.34

 

10.40 ± 0.99

 

Education

      

   < high school

2016

21.57

6.73 ± 0.42

0.0001

16.55 ± 1.36

< 0.0001

   Completed high school

1706

34.54

5.58 ± 0.32

 

12.67 ± 1.00

 

   > high school

1570

43.89

4.40 ± 0.30

 

7.02 ± 0.73

 

Smoking status

      

   Non-smoker

2748

47.10

4.88 ± 0.36

0.0595

10.28 ± 0.99

0.1464

   Former smoker

1294

26.54

5.86 ± 0.31

 

12.73 ± 1.09

 

   Current smoker

1279

26.36

5.26 ± 0.30

 

10.47 ± 1.20

 

Alcohol use

      

   None

2838

46.09

6.45 ± 0.29

< 0.0001

14.42 ± 1.20

0.0001

   1-3 drinks/week

1156

27.63

4.62 ± 0.38

 

7.76 ± 0.97

 

   ≥ 4 drinks/week

1145

26.28

4.07 ± 0.29

 

7.88 ± 1.15

 

Waist:hip ratio c

      

   Low

1565

35.89

4.57 ± 0.25

0.0007

6.29 ± 0.82

0.0001

   High

3539

64.11

5.56 ± 0.28

 

12.94 ± 1.11

 

Diabetes d

      

   No

4921

94.85

4.88 ± 0.23

< 0.0001

9.21 ± 0.64

< 0.0001

   Yes

399

5.15

18.96 ± 3.16

 

44.03 ± 4.98

 

Serum CRP level (mg/dL)

      

   < 1

4747

92.35

4.98 ± 0.25

< 0.0001

9.96 ± 0.63

< 0.0001

   ≥ 1

549

7.65

9.47 ± 0.99

 

23.68 ± 3.89

 

Hypertension e

      

   No

3653

75.32

4.21 ± 0.21

< 0.0001

6.09 ± 0.59

< 0.0001

   Yes

1659

24.68

10.26 ± 0.57

 

26.17 ± 1.95

 

eGFR (ml/min/1.73 m 2 )

      

   ≥ 60

4882

93.84

4.85 ± 0.24

< 0.0001

9.24 ± 0.74

< 0.0001

   < 60

406

6.16

16.16 ± 1.74

 

37.81 ± 2.85

 

ACR, albumin-to-creatinine ratio; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; NHANES III, Third National Health and Nutrition Examination Survey; SD, standard deviation; SE, standard error.

a) Weighted percentage based on NHANES survey weights. b) Defined as ACR ≥ 17 mg/g in men and ≥ 25 mg/g in women. c) Defined by sex-specific cut-offs: males = 0.90; females = 0.85. d) Defined as self-reported diabetes (answering "yes" to "ever been told you have sugar/diabetes"), but excluding women with a history of only gestational diabetes. e) Defined as systolic blood pressure (bp) ≥ 140 mmHg, diastolic bp ≥ 90 mmHg, or currently taking prescribed medicine for hypertension.

Allele frequencies of each of the included candidate gene polymorphisms are presented in Table 2. For 59 of the 60 variants (98.3%), the allele frequency varied significantly across race/ethnic groups (P < 0.05). There are several variants with substantial relative or absolute differences in allele frequency between populations (e.g., CRP variants rs3093058 and rs3093066).
Table 2

Weighted allele frequencies of polymorphisms examined in study participants, NHANES III DNA bank (1991-1994)

    

Non-Hispanic whites

(N = 2249)

Non-Hispanic blacks

(N = 1502)

Mexican Americans

(N = 1570)

 

Gene

Variant

Type/locationa

Alleles

Frequencyb(%)

HWP

P-value

Frequency (%)

HWP

P-value

Frequency (%)

HWP

P-value

P-valuec

ADRB2

rs1042713

Arg16Gly

A/G

38.7

0.4558

49.8

0.8106

40.7

0.3089

< 0.0001

 

rs1042714

Gln27Glu

G/C

41.6

0.8470

17.7

0.5914

21.7

0.8367

< 0.0001

APOE

rs429358

Cys130Arg

C/T

15.1

0.4694

22.1

0.4997

10.9

0.0177

0.0002

 

rs7412

Arg176Cys

T/C

8.2

0.7409

10.2

0.1013

3.5

0.4721

0.0004

CAT

rs769214

-843

G/A

33.9

0.8337

41.0

0.3725

50.2

0.4067

< 0.0001

CCL5

rs2280788

-95

G/C

3.0

0.0233

0.7

0.8085

1.2

0.6867

< 0.0001

CCR2

rs1799864

Val64Ile

A/G

9.5

0.3895

14.7

0.0828

22.0

0.8849

< 0.0001

CRP

rs1205

3'UTR

A/G

34.3

0.0620

21.1

0.0210

35.2

0.3485

< 0.0001

 

rs1417938

intronic

T/A

29.9

0.4841

11.8

0.9060

34.1

0.2799

< 0.0001

 

rs1800947

Leu184Leu

C/G

2.9

0.5732

0.8

0.7876

2.1

0.4574

0.0004

 

rs2808630

downstream of gene

G/A

28.5

0.8126

16.8

0.2494

21.8

0.4448

< 0.0001

 

rs3091244

-389

A/C

6.4

0.6077

26.3

0.7876

4.8

0.3901

< 0.0001

   

T/C

30.6

 

27.8

 

35.7

  
 

rs3093058

promoter

T/A

0.3

0.9146

15.9

0.8973

1.7

0.2351

< 0.0001

 

rs3093066

3' UTR

A/C

0.7

0.7812

22.3

0.9172

1.5

0.5234

< 0.0001

 

rs35500644

Thr35Thr

C/A

--d

 

2.0

0.5503

--

 

0.0003

 

rs11265260

upstream of gene

G/A

6.1

0.6833

7.1

0.6120

3.9

0.8988

0.0057

 

rs12093699

downstream of gene

A/G

30.5

0.4361

31.7

0.4314

34.8

0.5947

0.0286

 

rs12744244

downstream of gene

A/C

20.5

0.5659

4.3

0.2859

13.2

0.3447

< 0.0001

 

rs2027471

upstream of gene

A/T

34.5

0.2198

22.6

0.0701

36.9

0.3717

< 0.0001

 

rs2592887

downstream of gene

A/G

40.4

0.5556

49.0

0.9909

40.6

0.6631

< 0.0001

 

rs2794520

downstream of gene

A/G

33.6

0.2538

22.8

0.0354

35.5

0.7546

< 0.0001

 

rs3093075

downstream of gene

A/C

6.6

0.4684

26.2

0.9300

4.7

0.9636

< 0.0001

F2

rs1799963

upstream of gene

A/G

1.2

0.5214

0.3

0.8969

1.1

0.6927

0.0042

F5

rs6025

Arg534Gln

A/G

2.6

0.6247

0.6

0.8195

0.9

0.0101

< 0.0001

FCGR2A

rs1801274

His166Arg; His167Arg

G/A

51.1

0.0235

53.2

0.1480

52.9

0.9579

0.1412

FGB

rs1800790

-462

A/G

19.2

0.9227

5.5

0.0015

15.0

0.6910

< 0.0001

GCKR

rs1260326

Pro446Leu

T/C

43.3

0.3779

15.4

0.0016

34.2

0.3443

< 0.0001

IL1B

rs1143623

-2022

C/G

27.8

0.9893

11.0

0.6368

43.9

0.5735

< 0.0001

IL10

rs1800871

-853; -819

T/C

24.2

0.5168

39.3

0.9181

37.8

0.0123

< 0.0001

 

rs1800872

-626; -592

A/C

24.4

0.4456

38.9

0.6244

37.7

0.0145

< 0.0001

 

rs1800896

-1116; -1082

G/A

46.9

0.5030

35.6

0.3431

30.5

0.5009

< 0.0001

IL4

rs2243248

-1098

G/T

7.5

0.4678

15.6

0.6580

12.3

0.0577

< 0.0001

 

rs2243250

-588; -524;

-590

T/C

16.1

0.6836

64.7

0.1552

43.2

0.2281

< 0.0001

 

rs2243270

intronic

G/A

16.5

0.5225

64.1

0.0082

42.7

0.2506

< 0.0001

IL4R

rs1801275

Gln576Arg

G/A

21.3

0.7231

67.7

< 0.0001

28.6

0.5716

< 0.0001

 

rs1805015

Ser503Pro

C/T

16.3

0.6704

36.4

0.9842

15.5

0.2848

< 0.0001

ITGB3

rs5918

Leu59Pro

C/T

16.6

0.8121

9.8

0.9417

9.8

0.0677

< 0.0001

MBL2

rs11003125

-618; -550

G/C

35.8

0.8188

13.4

0.3698

51.3

0.4876

< 0.0001

 

rs1800450

Gly54Asp

A/G

14.4

0.0333

3.5

0.0388

14.4

0.4665

< 0.0001

 

rs1800451

Gly57Glu

A/G

2.1

0.1373

23.3

0.0131

2.8

0.2854

< 0.0001

 

rs5030737

Arg52Cys

T/C

6.8

0.5280

1.0

0.7461

2.5

0.0514

< 0.0001

 

rs7096206

-289; -221

C/G

22.5

0.2505

14.9

0.6554

11.0

0.0133

< 0.0001

NOS2A

rs1800482

promoter

C/G

--

 

6.7

0.4602

0.3

< 0.0001

< 0.0001

 

rs9282799

-2892; -1173

T/C

0.0

0.9579

4.5

0.5776

0.2

0.9494

< 0.0001

NOS3

rs1799983

Asp298Glu

T/G

32.6

0.3242

13.2

0.1706

19.4

0.1261

< 0.0001

 

rs2070744

-786

C/T

39.2

0.5881

15.6

0.0190

24.2

0.0251

< 0.0001

PON1

rs662

Gln192Arg

G/A

32.2

0.5369

67.3

0.9505

46.6

0.1891

< 0.0001

 

rs854560

Leu55Met

A/T

35.2

0.3791

18.0

0.4022

22.7

0.7799

< 0.0001

PPARG

rs1801282

Pro12Ala

G/C

13.5

0.9051

2.7

0.9100

12.3

0.5137

< 0.0001

SERPINE1

rs1799762

ins/del in promoter

4G/5G

53.0

0.6712

26.7

0.2376

33.5

0.4660

< 0.0001

TGFB1/B9D2

rs1800468

-800

A/G

7.8

0.8588

2.9

0.8929

5.0

0.6573

< 0.0001

 

rs1800469

-509

T/C

31.6

0.7314

24.6

0.8500

44.2

0.2589

< 0.0001

 

rs1800470

Pro10Leu

C/T

38.7

0.2483

45.8

0.5523

49.7

0.0675

< 0.0001

TLR4

rs4986790

Asp299Gly

G/A

6.6

0.2370

7.2

0.5877

2.6

0.2387

< 0.0001

TNF

rs1800629

-487; -308

A/G

17.1

0.4636

12.6

0.6949

6.9

0.8989

< 0.0001

 

rs1800750

-555

A/G

1.5

< 0.0001

2.4

0.1562

2.7

0.2652

0.0326

 

rs361525

-417; -238

A/G

5.9

0.0156

3.8

0.8423

5.9

0.2594

0.0040

VDR

rs2239185

intronic

C/T

47.9

0.0008

43.5

0.6865

58.6

0.7644

< 0.0001

 

rs731236

Ile352Ile; TaqI

C/T

38.2

0.2444

28.7

0.5501

23.8

0.2615

< 0.0001

Unknown

rs890945

unknown

A/T

20.8

0.5772

29.6

0.2610

29.9

0.8995

< 0.0001

HWP, Hardy-Weinberg proportions; NHANES III, Third National Health and Nutrition Examination Survey.

a) Alternate designations are given, if available. b) Weighted frequencies are presented for the first listed allele. c) Chi-square test of significance of the difference in allele frequency across race/ethnic groups. d) Cannot report due to disclosure concerns (small cell sizes).

Each polymorphism was tested individually for association with log(ACR) (as a continuous variable) and with albuminuria (as dichotomous variables) in univariate and multivariable regression models stratified by race/ethnic group. Two multivariable models were assessed: adjustment for age and (where appropriate) sex, and full adjustment for a number of demographic and clinical variables. Variants with results of P < 0.05 in additive genetic models prior to adjustment for the false-discovery rate (FDR) are presented in Tables 3, 4 and 5 (crude and fully-adjusted models only). Complete results for all individual polymorphisms under additive and codominant modes of inheritance are available in Additional File 1, Tables S1-S6.
Table 3

Significant associations of candidate gene polymorphisms and albumin-to-creatinine ratioa, additive genetic model

 

Crude Model

Fully AdjustedbModel

Variant

β coefficient (95% CI)

P-value

FDR-adjusted P-value

β coefficient (95% CI)

P-value

FDR-adjusted P-value

Non-Hispanic whites

      

rs1801274 (FCGR2A)

0.07 (-0.01-0.14)

0.0884

0.7950

0.09 (0.01-0.17)

0.0308

0.5610

rs1800790 (FGB)

-0.07 (-0.15-0.01)

0.0854

0.7950

-0.08 (-0.17--0.00)

0.0417

0.5610

rs11003125 (MBL2)

0.10 (0.03-0.17)

0.0058

0.1300

0.09 (0.02-0.15)

0.0131

0.3930

rs9282799 (NOS2A)

1.31 (0.58-2.04)

0.0011

0.0660

0.81 (0.00-1.62)

0.0490

0.5610

rs1800750 (TNF)

0.41 (0.13-0.70)

0.0065

0.1300

0.35 (0.09-0.60)

0.0092

0.3930

Non-Hispanic blacks

      

rs1205 (CRP)

-0.11 (-0.25-0.04)

0.1441

0.7663

-0.15 (-0.29--0.00)

0.0441

0.5471

rs1799963 (F2)

-0.88 (-2.20-0.44)

0.1810

0.7663

-0.96 (-1.88--0.04)

0.0411

0.5471

rs1800468 (TGFB1/B9D2)

-0.34 (-0.65--0.03)

0.0328

0.7663

-0.33 (-0.70-0.04)

0.0750

0.5471

Mexican Americans

      

rs1800482 (NOS2A)

-0.06 (-0.69-0.57)

0.8458

0.9877

-0.32 (-0.58--0.06)

0.0176

0.3520

rs9282799 (NOS2A)

0.67 (0.29-1.05)

0.0014

0.0840

0.58 (-0.44-1.59)

0.2513

0.9466

rs1799983 (NOS3)

-0.12 (-0.30-0.06)

0.1699

0.8693

-0.18 (-0.32--0.04)

0.0145

0.3520

rs1799762 (SERPINE1)

0.10 (0.01-0.19)

0.0295

0.5900

0.03 (-0.07-0.12)

0.5637

0.9466

CI, confidence interval; FDR, false-discovery rate.

a) Defined as log-transformed albumin-to-creatinine ratio (ACR) and analyzed as a continuous variable. b) Analyses adjusted for age, sex, alcohol consumption, educational attainment, and waist:hip ratio.

Table 4

Significant associations of candidate gene polymorphisms and sex-specific albuminuriaa, additive genetic model

 

Crude Model

Fully AdjustedbModel

Variant

OR (95% CI)

P-value

FDR-adjusted P-value

OR (95% CI)

P-value

FDR-adjusted P-value

Non-Hispanic whites

      

rs1800750 (TNF)

2.38 (1.56-3.63)

0.0003

0.0180

2.74 (1.34-5.61)

0.0079

0.2370

rs361525 (TNF)

1.59 (1.07-2.36)

0.0235

0.7050

1.99 (1.23-3.25)

0.0075

0.2370

rs731236 (VDR)

1.27 (1.01-1.58)

0.0404

0.7904

1.16 (0.95-1.42)

0.1278

0.9818

Non-Hispanic blacks

      

rs2808630 (CRP)

1.39 (1.12-1.72)

0.0041

0.2460

1.30 (1.04-1.64)

0.0232

0.4515

rs3093058 (CRP)

0.67 (0.49-0.91)

0.0134

0.4020

0.66 (0.48-0.89)

0.0091

0.4515

rs7096206 (MBL2)

0.70 (0.50-0.99)

0.0423

0.5340

0.66 (0.44-1.01)

0.0530

0.5280

rs1800468 (TGFB1/B9D2)

0.48 (0.24-0.96)

0.0384

0.5340

0.44 (0.18-1.05)

0.0622

0.5280

rs1800629 (TNF)

0.69 (0.47-0.99)

0.0468

0.5340

0.79 (0.54-1.16)

0.2172

0.8145

rs731236 (VDR)

1.25 (0.98-1.59)

0.0736

0.6309

1.33 (1.03-1.72)

0.0301

0.4515

rs890945 (Chr 5q33.3)

0.78 (0.61-1.00)

0.0534

0.5340

0.71 (0.53-0.95)

0.0236

0.4515

Mexican Americans

      

rs11265260 (CRP)

0.39 (0.21-0.72)

0.0041

0.1121

0.51 (0.29-0.92)

0.0274

0.3202

rs3093075 (CRP)

0.40 (0.22-0.75)

0.0057

0.1121

0.45 (0.26-0.80)

0.0088

0.2069

rs1143623 (IL1B)

1.24 (1.09-1.40)

0.0022

0.1121

1.46 (1.28-1.67)

< 0.0001

< 0.0001

rs1800871 (IL10)

1.29 (1.03-1.62)

0.0267

0.3151

1.22 (0.91-1.62)

0.1753

0.5084

rs1800872 (IL10)

1.30 (1.04-1.64)

0.0242

0.3151

1.22 (0.91-1.63)

0.1673

0.5084

rs2070744 (NOS3)

0.76 (0.54-1.08)

0.1157

0.5012

0.67 (0.47-0.95)

0.0276

0.3202

rs1800629 (TNF)

0.63 (0.38-1.04)

0.0697

0.4745

0.56 (0.36-0.86)

0.0107

0.2069

CI, confidence interval; FDR, false-discovery rate; OR, odds ratio.

a) Defined as urinary albumin-to-creatinine ratio (ACR) above sex-specific thresholds (≥ 17 mg/g in men and ≥ 25 mg/g in women). b) Analyses adjusted for age, alcohol consumption, educational attainment, and waist:hip ratio.

Table 5

Significant associations of candidate gene polymorphisms and single-threshold albuminuriaa, additive genetic model

 

Crude Model

Fully AdjustedbModel

Variant

OR (95% CI)

P-value

FDR-adjusted P-value

OR (95% CI)

P-value

FDR-adjusted P-value

Non-Hispanic whites

      

rs1260326 (GCKR)

1.19 (0.92-1.53)

0.1774

0.8886

1.29 (1.02-1.64)

0.0361

0.6200

rs1800750 (TNF)

3.20 (2.06-4.98)

< 0.0001

< 0.0001

3.60 (1.65-7.88)

0.0025

0.1500

rs361525 (TNF)

1.71 (1.18-2.47)

0.0060

0.1800

1.94 (1.17-3.22)

0.0128

0.3840

rs2239185 (VDR)

0.81 (0.67-0.97)

0.0246

0.4020

0.84 (0.70-1.02)

0.0817

0.6200

rs731236 (VDR)

1.31 (1.03-1.65)

0.0268

0.4020

1.26 (0.99-1.61)

0.0612

0.6200

Non-Hispanic blacks

      

rs1205 (CRP)

0.75 (0.60-0.95)

0.0195

0.5655

0.74 (0.56-0.98)

0.0394

0.7760

rs3093058 (CRP)

0.74 (0.54-1.01)

0.0584

0.5942

0.72 (0.52-0.99)

0.0466

0.7760

rs1800468 (TGFB1/B9D2)

0.22 (0.06-0.76)

0.0193

0.5655

0.12 (0.01-0.99)

0.0493

0.7760

Mexican Americans

      

rs1800947 (CRP)

0.37 (0.08-1.77)

0.2022

0.6802

0.08 (0.03-0.20)

< 0.0001

< 0.0001

rs1143623 (IL1B)

1.30 (1.06-1.60)

0.0149

0.4321

1.55 (1.28-1.87)

0.0001

0.0029

rs1800871 (IL10)

1.24 (1.02-1.51)

0.0361

0.5234

1.14 (0.84-1.55)

0.3759

0.9181

rs1800872 (IL10)

1.25 (1.03-1.52)

0.0290

0.5234

1.15 (0.84-1.56)

0.3630

0.9181

rs1799983 (NOS3)

0.65 (0.39-1.10)

0.1046

0.6067

0.60 (0.37-0.98)

0.0423

0.4089

rs2070744 (NOS3)

0.66 (0.51-0.85)

0.0028

0.1624

0.62 (0.48-0.80)

0.0008

0.0155

rs1800629 (TNF)

0.75 (0.45-1.27)

0.2729

0.6914

0.65 (0.43-0.98)

0.0414

0.4089

CI, confidence interval; FDR, false-discovery rate; OR, odds ratio.

a) Defined as urinary albumin-to-creatinine ratio (ACR) above ≥ 30 mg/g regardless of gender. b) Analyses adjusted for age, sex, alcohol consumption, educational attainment, and waist:hip ratio.

In additive models, no more than five variants were associated with log(ACR) in any race/ethnic group in crude or fully-adjusted analyses (uncorrected P values < 0.05; Table 3). The results of models adjusting only for age and sex were similar to the fully-adjusted models for each variant in each race/ethnicity (Additional File 1, Table S1). Only one association with log(ACR) was statistically significant in any of the race/ethnic groups after adjustment for multiple testing: TNF variant rs1800750 in non-Hispanic whites in age-sex adjusted models (Additional File 1, Table S1). Of note, rs1800750 failed the test for Hardy-Weinberg proportions in this population (P < 0.0001, Table 2). Association results for log(ACR) were similar when tested in codominant models, and no FDR-adjusted P value reached statistical significance (Additional File 1, Table S2).

When albuminuria was defined as a dichotomous variable using sex-specific cutoffs, variants in TNF and VDR were associated with increased odds of albuminuria in non-Hispanic whites under an additive genetic model (Table 4 and Additional File 1, Table S3). After adjustment for multiple testing, only TNF variant rs1800750 was statistically significant in crude (FDR-P = 0.0180) and age-adjusted (FDR-P = 0.0059) models. Among non-Hispanic blacks, variants in CRP, MBL2, TGFB1/B9D2, TNF, VDR and an unknown gene (rs890945) had uncorrected P values <0.05 in crude or multivariable models. However, none of these findings were statistically significant after adjustment for multiple testing. In Mexican Americans, variants in CRP, IL1B, IL10, NOS3, PON1, and TNF were marginally associated (uncorrected P value < 0.05) with the odds of sex-specific albuminuria in one or more regression models. Of these, only IL1B variant rs1143623 remained significantly associated after correction for multiple testing (age-adjusted: OR = 1.36, FDR-P = 0.0058; fully-adjusted OR = 1.46, FDR-P < 0.0001) (Table 4 and Additional File 1, Table S3). Several of the variants found marginally associated with albuminuria under an additive model were also marginally associated in codominant models, although none reach statistical significance after FDR adjustment (Additional File 1, Table S4).

Compared to the results with sex-specific albuminuria, findings were not remarkably different when using the single-threshold definition of albuminuria (Table 5 and Additional File 1, Table S5). In the non-Hispanic white population, only TNF rs1800750 remained significantly associated with albuminuria in crude and age-sex adjusted additive genetic models. In non-Hispanic blacks, fewer polymorphisms were marginally associated with single threshold albuminuria than with sex-specific albuminuria; and none remained significant after FDR adjustment. In contrast, among Mexican Americans many of the same variants as with sex-specific albuminuria had uncorrected P-values < 0.05 for urinary ACR ≥ 30 mg/g. Three variants remained significantly associated in fully-adjusted additive models after correcting for multiple testing: rs1800947 in CRP (FDR-P value < 0.0001), rs1143623 in IL1B (FDR- P value = 0.0029), and rs2070744 in NOS3 (FDR-P = 0.0155). In age-sex adjusted models, the IL1B and NOS3 variants were also significantly associated with this outcome (Additional File 1, Table S5). In codominant models, the only variant significantly associated with the odds of single-threshold albuminuria was CRP rs1800947 among Mexican Americans (fully-adjusted model only, FDR-P < 0.0001; Table 5 and Additional File 1, Table S6).

To increase the sample size for these analyses, we also tested all participants as one group and adjusted for race/ethnicity in all regression models. Findings for each outcome in both additive and codominant genetic models were largely consistent with the race-stratified analyses for non-Hispanic whites (data not shown). The only variant to remain significant after FDR adjustment was TNF rs1800750, which was associated with increased prevalence of albuminuria (single-threshold and sex-specific) in at least one multivariable additive genetic model. No variants remained significant in codominant models for any outcome after correction for multiple testing (data not shown).

Haplotype analyses were conducted for the thirteen genes containing at least two genotyped polymorphisms. The C-G-C-G-G haplotype of MBL2 in non-Hispanic whites (crude model) and the A-C-C haplotype of CRP in non-Hispanic blacks (fully-adjusted model) were associated with decreased ACR after FDR adjustment (Additional File 1, Table S7). Among Mexican Americans, haplotypes within ADRB2 (A-G), IL4R (C-A), and VDR (T-T) were associated with log(ACR) in crude genetic models (FDR-P values < 0.05). For these haplotypes, age-sex adjusted models were only marginally associated with log(ACR) (data not shown). The C-T haplotype of NOS3 was statistically associated with decreased odds of categorically-defined albuminuria, in fully-adjusted models among Mexican Americans (FDR-P = 0.0220 for sex-specific albuminuria and < 0.0001 for ACR ≥ 30 mg/g). Across all populations, the only significant association in age-sex (where appropriate) adjusted models is the NOS3 C-T haplotype in relation to single-threshold albuminuria in Mexican Americans (OR = 0.38; uncorrected P = 0.0006; FDR-P = 0.0144) (data not shown). No other individual haplotypes or global tests for haplotype effect indicated a significant association with log(ACR) or albuminuria after adjustment for multiple testing (Additional File 1, Table S7). APOE isoforms were assessed individually (additive model) and in combination (codominant model). Of note, the T-T isoform (also known as ε2) was marginally associated with increased odds of sex-specific albuminuria among non-Hispanic blacks after full adjustment for covariates (OR: 1.51, 95% CI: 1.03, 2.21; uncorrected P = 0.0366), but not in crude or age-adjusted genetic models (data not shown). No other isoforms of APOE were associated with any outcome in any race/ethnic group, nor were any global tests of APOE isoforms significant in additive or codominant models.

Discussion

Inflammation is a suspected cause of kidney damage; and we were interested in testing associations of genes involved in the inflammatory response with urinary albumin excretion. We describe here the results of this work carried out with adults who participated in NHANES III, a population-based sample survey that is nationally representative of the U.S. population. We restricted analyses to albuminuria outcomes instead of chronic kidney disease, since the genes that influence renal function may differ from those contributing to renal damage and proteinuria [5153]. Many of the included genes are involved in other cellular or physiologic pathways, such as lipid metabolism (e.g., APOE, PPARG), hemostasis (e.g., F2, F5, FGB), and oxidative stress/nitric oxide production (e.g., PON1, CAT, NOS2A, NOS3).

It is unknown whether polymorphisms in inflammation genes affect the normal variation in urinary albumin excretion in humans, or whether such genetic variation plays a role only in the susceptibility to renal damage once some sort of ischemic or toxic insult is acquired. Our results only minimally support a role for such polymorphisms in the establishment of normal urinary albumin excretion, since all but one individual genotype and few haplotypes were significantly associated with continuous log(ACR) after adjustment for multiple testing. We do show that increasing minor allele copy number of polymorphisms in TNF in non-Hispanic whites (crude and age-adjusted models) and IL1B in Mexican Americans (both multivariable models) were associated with albuminuria as defined by sex-specific criteria. However, TNF rs1800750 failed the test for Hardy-Weinberg proportions in non-Hispanic whites, so this result should be interpreted cautiously. No polymorphisms were associated with sex-specific albuminuria in codominant models in any race/ethnic group. For comparison, we also analyzed data for albuminuria defined by a single threshold for both men and women. These analyses yielded results similar to those for sex-specific albuminuria, though among Mexican Americans, genetic variants in CRP and NOS3 were also significantly associated with ACR ≥ 30 mg/g under additive models. This CRP variant (rs1800947) was also the only polymorphism significantly associated with single-threshold albuminuria in codominant models after correcting for multiple testing (FDR-P < 0.0001). The significance of this variant only after full multivariable adjustment may be due to instability of the regression model because of the low allele frequency of rs1800947 in Mexican Americans. CRP haplotypes were not associated with single threshold albuminuria in Mexican Americans, though rare CRP haplotypes as a group were marginally associated (uncorrected P value < 0.05) with sex-specific ACR. The C-T haplotype of NOS3 was found to be significantly associated with both definitions of albuminuria in Mexican Americans, strongly implicating this gene in the susceptibility to kidney damage. We found no evidence of an effect of other haplotypes on the odds of albuminuria after adjusting for multiple testing.

We calculated the power of our study to detect associations of individual polymorphisms with log(ACR) and sex-specific albuminuria within each race/ethnic group, using a two-sided α set at 0.05 and assuming a design effect of 1.2. For log(ACR), we calculated power to detect effect sizes consistent with an R2 of 0.5%. In non-Hispanic whites, we have 86% power to detect changes in the log(ACR) beta coefficient of 0.41 and 0.25 at minor allele frequencies (MAFs) of 10% and 40%, respectively. In non-Hispanic blacks, our power is 70% to detect changes in the beta of 0.33 and 0.20 at the same MAFs. For Mexican-Americans, changes in the beta coefficient of 0.45 (at 10% MAF) and 0.28 (at 40% MAF) could be detected with 72% power. For sex-specific albuminuria, we calculated the study power for an odds ratio of 1.3, which is indicative of effects found both in candidate gene studies [54] and in genome-wide association studies [55]. At MAFs of 10% and 40%, the power to detect an OR = 1.3 in non-Hispanic whites is 32% and 64%, respectively. In non-Hispanic blacks, power is 18% and 36%, respectively, at these MAFs. For the Mexican American population, study power to detect an OR = 1.3 is 24% and 49% at MAFs of 10% and 40%, respectively.

Few published studies have assessed the association of inflammation-related genes with albuminuria. No association with albuminuria was found for the TGFB1 Pro10Leu (rs1800470) variant in non-diabetic Chinese [56]. Neither -509C > T (rs1800469) nor rs1800470 was found associated with urine albumin levels or albuminuria in hypertensive Italian men [57], though the TC and CC genotypes of the Pro10Leu variant was found associated with albuminuria and urine albumin excretion in a separate study of Italian hypertensive patients [58]. NOS3 -786T > C (rs2070744), but not Asp298Glu (rs1799983), was positively associated with increased ACR and higher risk of albuminuria in diabetic and nondiabetic European American family members [59]. Neither variant was associated with urine albumin excretion or albuminuria in a smaller study of hypertensive white men [60]; nor was the Asp298Glu variant associated with urinary albumin excretion in healthy Venezuelans [61]. Neither NOS3 variant was associated with ACR in a family-based study of Mexican Americans [62], a finding not completely supported by our study. The AA genotype of PON1 variant rs662 (Gln192Arg) was recently found associated with albuminuria in a large study of Japanese, but only among women [63]. Genetic variation in the CCL5 gene has been associated with ACR in a non-diabetic Japanese population, but the -95C > G variant (rs2280788) included in our analyses was not studied [64]. The Pro12Ala variant (rs1801282) of PPARG has been associated with urinary albumin excretion in a type 2 diabetic population [65]. The well studied APOE variants rs429358 and rs7412, from which the APOE ε2, ε3, and ε4 alleles (isoforms) are composed, were weakly associated with glomerular filtration rate (a measure of kidney function) in non-Hispanic whites and non-Hispanic blacks in NHANES III, but kidney damage was not assessed separately [39]. In one study that assessed progression of chronic kidney disease, APOE genotypes were not significantly associated with macroalbuminuria (ACR ≥ 300 μg/mg) [66]. Studies of MBL2 variants have been limited primarily to type 1 diabetic populations, in which there are conflicting data on the role of MBL2 polymorphisms in diabetic nephropathy [67, 68]. To our knowledge, there have been no published genetic association studies of urinary albumin excretion or albuminuria that included variants in many of the genes in which we found polymorphisms or haplotypes significantly associated with any outcome in at least one race/ethnic group (e.g., CRP, IL1B, TNF, or VDR).

Studies such as ours are complicated by the fact that the assessment of albuminuria in any population is not straightforward. Though the gold standard for the quantitative evaluation of proteinuria is a 24-hr urine collection, this method is inconvenient and is prone to errors [28]. For the screening of adults for proteinuria, various organizations recommend measurement of an untimed (i.e., spot) urine sample using a ratio of albumin to creatinine [69]. This use of a ratio corrects for variability due to hydration, diuretics, osmotic diuresis, and concentrating defects [28, 70] and has been shown to correlate well with 24-hr urine albumin excretion measurements [28, 71, 72]. Most often, albuminuria is defined as urinary ACR ≥ 30 mg/g for both men and women. Sex-specific criteria have been advocated in order to account for greater creatinine excretion in men than in women [30, 7375], though there are no explicit recommendations for use of such criteria [28]. Importantly, given the strong predictive value of even low-grade albuminuria for cardiovascular disease, it has been suggested that albuminuria be interpreted as a continuum rather than as threshold cut-off values, as dichotomizing albuminuria results in the loss of important clinical information [5, 76]. Therefore, we analyzed urinary ACR as both a continuous variable and as dichotomous variables. We did not adjust for hypertension or diabetes in our analyses as these conditions are major risk factors for chronic kidney disease. The genetic associations examined here may have been distorted if the included polymorphisms act, at least partially, via these causal pathways to affect urine albumin excretion.

Statistical analyses were performed for individual polymorphisms under two modes of inheritance. Additive models detect both additive and dominant genetic loci effectively, but perform poorly for recessive alleles [77, 78]. Codominant models have the best performance when the true inheritance pattern is unknown [77, 78]. However, codominant models seemed to be less robust in situations of low MAF, such that our estimates may be less stable and our power to identify a recessive effect poor. Furthermore, odds ratios could not be estimated for some codominant models when the MAF was very low.

Our study has several limitations, some of which are specific to analyses in NHANES. First, we included one spot urine sample for the measurement of urinary ACR, as repeat tests were performed only in a small subset of NHANES III participants [1, 79]. Therefore, we could not differentiate between participants with persistent albuminuria and those with transiently elevated urinary ACR. The use of the single albuminuria measurement could misclassify cases and controls and bias our results since agreement between initial and repeat urine tests was not perfect [1, 28, 79]. Secondly, because NHANES III is a nationally representative study, there were few participants with severe kidney damage. In fact, only a very small proportion (N = 128; 1.03 ± 0.18%) of persons in our study population displayed clinical proteinuria (ACR ≥ 250 mg/g in men or ≥ 355 mg/g in women). This may have hampered our ability to detect genetic associations with log(ACR) or albuminuria. Also, we did not perform separate analyses for diabetics or hypertensives as the resulting sample size within each race/ethnic group would have been limiting. However, there is some evidence that similar genes may contribute to ACR in both nondiabetic and diabetic individuals [80]. Furthermore, we were unable to assess population stratification in our analyses, as data from ancestry-informative markers are not yet available for NHANES III. The large sample size of NHANES III did allow for separate analyses within each of the three main race/ethnic groups, self-reported designations that have been shown to correspond with ancestry as derived from ancestry-informative markers for these populations [8185]. These race/ethnic group-stratified analyses enabled us to account at least partially for differences in albuminuria profile, allele frequencies, and linkage disequilibrium patterns between race/ethnicities. We cannot, however, discount that there may be residual population substructure within the race/ethnic groups that may have affected our results. Therefore, caution should be exercised in interpreting our findings, especially in non-Hispanic blacks and Mexican Americans, since these populations have experienced recent genetic admixture. In addition, the lack of "replication" of marginally associated (uncorrected P-value < 0.05) or significantly associated variants across race/ethnic groups may be due to differences in the underlying linkage disequilibrium patterns of the populations, due to untested interactions, or due to lack of power. Indeed, for categorical outcomes, our power to detect a typical effect size (OR = 1.3) in each race/ethnic group was modest. The combined analyses that included all participants and adjusted for race/ethnicity did not affect our overall findings, as the statistical weighting of the race/ethnic groups produced results not materially different than those found in non-Hispanic whites alone.

A couple of limitations are not specific to NHANES. Defining albuminuria with sex-specific criteria does not alleviate all concerns regarding the measurement of urine albumin excretion. It has been proposed that additional urinary ACR thresholds that account for differences by age [86, 87] and race/ethnicity [30, 74] may be needed to avoid misclassification of certain demographic groups, though no specific guidelines have been developed. In addition, the use of FDR-adjusted P values to determine statistical significance may be overly conservative, as the assumption of independent tests is not met given that some polymorphisms are correlated owing to linkage disequilibrium.

The NHANES data are a unique resource for epidemiologic analyses in a large, population-based and nationally representative sample of the U.S. population. Our findings are generalizeable to the larger U.S. population and point to a few genes that may play a role in the susceptibility to albuminuria. Ideally, we could have included other variants known to be related to the progression and severity of renal disease, such as those within inflammatory cytokine IL-6 and polymorphisms identified in a recent genome-wide association study as significantly associated with urine albumin excretion [36]. Such variants, however, have not yet been genotyped in NHANES III. NHANES should be used for additional research into the associations between genetic variants and renal disease and to evaluate the importance of gene-environment interactions.

Conclusions

We report the association of a small set of polymorphisms and haplotypes in genes involved in inflammation with albuminuria-related outcomes. This study is the first to examine genetic associations with such outcomes using a population-based and nationally representative sample of the U.S. population. Additional studies are needed to further assess genetic variation in these, and untested, inflammation genes and the susceptibility to kidney damage. Furthermore, NHANES can be used to facilitate the population-level assessment of new and validated polymorphisms for kidney disease susceptibility.

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Abbreviations

ACR: 

albumin-to-creatinine ratio

CDC: 

Centers for Disease Control and Prevention

CRP: 

C-reactive protein

CVD: 

cardiovascular disease

eGFR: 

estimated glomerular filtration rate

FDR: 

false discovery rate

IL1B

interleukin 1 beta

IL-6: 

interleukin 6

MAF: 

minor allele frequency

NCHS: 

National Center for Health Statistics

NHANES III: 

Third National Health and Nutrition Examination Survey

NOS3

nitric oxide synthase 3 (endothelial cell)

TNF-α: 

tumor necrosis factor alpha.

Declarations

Acknowledgements

This study was made possible through the efforts of the CDC/NCI NHANES III Genomics Working Group and funding by the Office of Public Health Genomics at CDC. For the nine polymorphisms genotyped by the custom Illumina GoldenGate assay, genotyping services were provided by the Johns Hopkins University under U.S. Federal Government contract number N01-HV-48195 from the National Heart, Lung, and Blood Institute. Special thanks to Muin J. Khoury, M.D., Ph.D. (Director of the Office of Public Health Genomics at CDC) for oversight of the project and to the staff of the Research Data Center at NCHS for their data support and assistance in disclosure review.

Authors’ Affiliations

(1)
Office of Public Health Genomics, Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention
(2)
Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention
(3)
American Society of Human Genetics Fellow, Centers for Disease Control and Prevention
(4)
Office of Minority Health and Health Disparities, Office of the Director, Centers for Disease Control and Prevention

References

  1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA. 2007, 298: 2038-2047. 10.1001/jama.298.17.2038.View ArticlePubMedGoogle Scholar
  2. Snyder JJ, Foley RN, Collins AJ: Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2009, 53: 218-228. 10.1053/j.ajkd.2008.07.034.View ArticlePubMedGoogle Scholar
  3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, et al: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003, 108: 2154-2169. 10.1161/01.CIR.0000095676.90936.80.View ArticlePubMedGoogle Scholar
  4. Weir MR: Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007, 2: 581-590. 10.2215/CJN.03190906.View ArticlePubMedGoogle Scholar
  5. Danziger J: Importance of low-grade albuminuria. Mayo Clin Proc. 2008, 83: 806-812. 10.4065/83.7.806.View ArticlePubMedGoogle Scholar
  6. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, Kusek JW, Byrd-Holt D, Narayan KM, Herman WH, et al: Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002, 39: 445-459. 10.1053/ajkd.2002.31388.View ArticlePubMedGoogle Scholar
  7. de Zeeuw D, Parving HH, Henning RH: Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006, 17: 2100-2105. 10.1681/ASN.2006050517.View ArticlePubMedGoogle Scholar
  8. Stehouwer CD, Smulders YM: Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol. 2006, 17: 2106-2111. 10.1681/ASN.2005121288.View ArticlePubMedGoogle Scholar
  9. Trepels T, Zeiher AM, Fichtlscherer S: The endothelium and inflammation. Endothelium. 2006, 13: 423-429. 10.1080/10623320601061862.View ArticlePubMedGoogle Scholar
  10. Zernecke A, Weber C: Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol. 2005, 100: 93-101. 10.1007/s00395-005-0511-6.View ArticlePubMedGoogle Scholar
  11. Barzilay JI, Peterson D, Cushman M, Heckbert SR, Cao JJ, Blaum C, Tracy RP, Klein R, Herrington DM: The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis. 2004, 44: 25-34. 10.1053/j.ajkd.2004.03.022.View ArticlePubMedGoogle Scholar
  12. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM: Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000, 58: 1703-1710. 10.1046/j.1523-1755.2000.00331.x.View ArticlePubMedGoogle Scholar
  13. Kshirsagar AV, Bomback AS, Bang H, Gerber LM, Vupputuri S, Shoham DA, Mazumdar M, Ballantyne CM, Paparello JJ, Klemmer PJ: Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol. 2008, 101: 401-406. 10.1016/j.amjcard.2007.08.041.View ArticlePubMedGoogle Scholar
  14. Navarro JF, Mora C, Maca M, Garca J: Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003, 42: 53-61. 10.1016/S0272-6386(03)00408-6.View ArticlePubMedGoogle Scholar
  15. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G: Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese nondiabetic premenopausal women. J Intern Med. 2001, 250: 502-507. 10.1046/j.1365-2796.2001.00914.x.View ArticlePubMedGoogle Scholar
  16. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD: Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study. Diabetologia. 2005, 48: 370-378. 10.1007/s00125-004-1628-8.View ArticlePubMedGoogle Scholar
  17. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vac Biol. 2002, 22: 593-598. 10.1161/01.ATV.0000013786.80104.D4.View ArticleGoogle Scholar
  18. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002, 51: 1157-1165. 10.2337/diabetes.51.4.1157.View ArticlePubMedGoogle Scholar
  19. Freedman BI, Bostrom M, Daeihagh P, Bowden DW: Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007, 2: 1306-1316. 10.2215/CJN.02560607.View ArticlePubMedGoogle Scholar
  20. Ruster C, Wolf G: The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci. 2008, 13: 944-955. 10.2741/2734.View ArticlePubMedGoogle Scholar
  21. Zintzaras E, Papathanasiou AA, Stefanidis I: Endothelial nitric oxide synthase gene polymorphisms and diabetic nephropathy: a HuGE review and meta-analysis. Genet Med. 2009, 11: 695-706. 10.1097/GIM.0b013e3181b2046b.View ArticlePubMedGoogle Scholar
  22. Nordfors L, Lindholm B, Stenvinkel P: End-stage renal disease--not an equal opportunity disease: the role of genetic polymorphisms. J Intern Med. 2005, 258: 1-12. 10.1111/j.1365-2796.2005.01516.x.View ArticlePubMedGoogle Scholar
  23. National Health and Nutrition Examination Survey. [http://www.cdc.gov/nchs/nhanes.htm]
  24. NHANES III Data Files, Documentation, and SAS Code. [http://www.cdc.gov/nchs/nhanes/nh3data.htm]
  25. National Center for Health Statistics: Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94. 1994, Hyattsville, MD: National Center for Health Statistics, (Vital and Health Statistics, Series 1: Programs and Collection Procedures, no. 32) (DHHS publication no. (PHS) 94-1308) (GPO no. 017-022-01260-0), [http://www.cdc.gov/nchs/data/series/sr_01/sr01_032.pdf]Google Scholar
  26. NHANES Genetic Data. [http://www.cdc.gov/nchs/nhanes/genetics/genetic.htm]
  27. Chang M, Lindegren ML, Butler MA, Chanock SJ, Dowling NF, Gallagher M, Moonesinghe R, Moore CA, Ned RM, Reichler M, et al: Prevalence in the United States of Selected Candidate Gene Variants: Third National Health and Nutrition Examination Survey, 1991-1994. Am J Epidemiol. 2009, 169: 54-66. 10.1093/aje/kwn286.View ArticlePubMedGoogle Scholar
  28. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002, 39: S1-266. 10.1016/S0272-6386(02)70081-4.
  29. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, et al: National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003, 111: 1416-1421. 10.1542/peds.111.6.1416.View ArticlePubMedGoogle Scholar
  30. Jacobs DR, Murtaugh MA, Steffes M, Yu X, Roseman J, Goetz FC: Gender- and race-specific determination of albumin excretion rate using albumin-to-creatinine ratio in single, untimed urine specimens: the Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol. 2002, 155: 1114-1119. 10.1093/aje/155.12.1114.View ArticlePubMedGoogle Scholar
  31. The GeneCards Human Gene Database. [http://www.genecards.org]
  32. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000, 25: 25-29. 10.1038/75556.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S: AmiGO: online access to ontology and annotation data. Bioinformatics. 2009, 25: 288-289. 10.1093/bioinformatics/btn615.View ArticlePubMedGoogle Scholar
  34. Yee YK, Chintalacharuvu SR, Lu J, Nagpal S: Vitamin D receptor modulators for inflammation and cancer. Mini Rev Med Chem. 2005, 5: 761-778. 10.2174/1389557054553785.View ArticlePubMedGoogle Scholar
  35. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE, Kwiatkowski D, Cook NR, Miletich JP, Chasman DI: Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet. 2008, 82: 1185-1192. 10.1016/j.ajhg.2008.03.015.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Hwang SJ, Yang Q, Meigs JB, Pearce EN, Fox CS: A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study. BMC Med Genet. 2007, 8 (Suppl 1): S10-10.1186/1471-2350-8-S1-S10.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Keebler ME, Sanders CL, Surti A, Guiducci C, Burtt NP, Kathiresan S: Association of Blood Lipids With Common DNA Sequence Variants at 19 Genetic Loci in the Multiethnic United States National Health and Nutrition Examination Survey III. Circ Cardiovasc Genet. 2009, 2: 238-243. 10.1161/CIRCGENETICS.108.829473.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Crawford DC, Sanders CL, Qin X, Smith JD, Shephard C, Wong M, Witrak L, Rieder MJ, Nickerson DA: Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation. 2006, 114: 2458-2465. 10.1161/CIRCULATIONAHA.106.615740.View ArticlePubMedGoogle Scholar
  39. Chu AY, Parekh RS, Astor BC, Coresh J, Berthier-Schaad Y, Smith MW, Shuldiner AR, Kao WH: Association of APOE polymorphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study. BMC Med Genet. 2009, 10: 108-10.1186/1471-2350-10-108.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Gunter EW, Lewis BG, Koncikowski SM: Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. 1996, National Center for Environmental Health and National Center for Health Statistics, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Atlanta, GA and Hyattsville, MD, [http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/labman.pdf]Google Scholar
  41. Levey A, Coresh J, Greene T, Marsh J, Stevens L, Kusek J, Van Lente F: Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values [abstract]. J Am Soc Nephrol. 2005, 16: 69A-abstractGoogle Scholar
  42. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F: Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007, 53: 766-772. 10.1373/clinchem.2006.077180.View ArticlePubMedGoogle Scholar
  43. National Kidney Disease Education Program (NKDEP). Laboratory Professionals: Equations and GFR Calculators. [http://www.nkdep.nih.gov/labprofessionals/equations_and_GFR.htm]
  44. Selvin E, Manzi J, Stevens LA, Van Lente F, Lacher DA, Levey AS, Coresh J: Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis. 2007, 50: 918-926. 10.1053/j.ajkd.2007.08.020.View ArticlePubMedGoogle Scholar
  45. Binder D: On the variance of asymptotically normal estimators from complex surveys. Int Stat Rev. 1983, 51: 279-292. 10.2307/1402588.View ArticleGoogle Scholar
  46. Woodruff R: A simple method for approximating the variance of a complicated estimate. J Am Stat Assoc. 1971, 66: 411-414. 10.2307/2283947.View ArticleGoogle Scholar
  47. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG: Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered. 2002, 53: 79-91. 10.1159/000057986.View ArticlePubMedGoogle Scholar
  48. Parsons VL: Using the Sampling Design in Logistic Regression Analysis of NCHS Survey Data-- Some Applications. Proceedings of the Survey Research Methods Section, American Statistical Association (ASA). 1992, Alexandria, VA: American Statistical Association, 327-332.Google Scholar
  49. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001, 125: 279-284. 10.1016/S0166-4328(01)00297-2.View ArticlePubMedGoogle Scholar
  50. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995, 57: 289-300.Google Scholar
  51. Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, Bowden DW, Duggirala R, Elston RC, Hanson RL, et al: Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Diabetes. 2007, 56: 1577-1585. 10.2337/db06-1154.View ArticlePubMedGoogle Scholar
  52. Placha G, Canani LH, Warram JH, Krolewski AS: Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. Adv Chronic Kidney Dis. 2005, 12: 155-169. 10.1053/j.ackd.2005.02.002.View ArticlePubMedGoogle Scholar
  53. Leon JM, Freedman BI, Miller MB, North KE, Hunt SC, Eckfeldt JH, Lewis CE, Kraja AT, Djousse L, Arnett DK: Genome scan of glomerular filtration rate and albuminuria: the HyperGEN study. Nephrol Dial Transplant. 2007, 22: 763-771. 10.1093/ndt/gfl674.View ArticlePubMedGoogle Scholar
  54. Ioannidis JP, Trikalinos TA, Khoury MJ: Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol. 2006, 164: 609-614. 10.1093/aje/kwj259.View ArticlePubMedGoogle Scholar
  55. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA: Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA. 2009, 106: 9362-9367. 10.1073/pnas.0903103106.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Hu BC, Chu SL, Wang GL, Gao PJ, Zhu DL, Wang JG: Association between genetic variation in transforming growth factors beta1 and beta3 and renal dysfunction in non-diabetic Chinese. Clin Exp Hypertens. 2008, 30: 121-131. 10.1080/10641960801931907.View ArticlePubMedGoogle Scholar
  57. Dell'Omo G, Penno G, Pucci L, Lucchesi D, Del Prato S, Pedrinelli R: Lack of association between TGF-beta-1 genotypes and microalbuminuria in essential hypertensive men. Nephrol Dial Transplant. 2009, 24: 1864-1869. 10.1093/ndt/gfn754.View ArticlePubMedGoogle Scholar
  58. Argano C, Duro G, Corrao S, Di Chiara T, Nuzzo D, Colomba D, Scaglione R, Licata G: Transforming growth factor beta1 T29C gene polymorphism and hypertension: relationship with cardiovascular and renal damage. Blood Press. 2008, 17: 220-226. 10.1080/08037050802431416.View ArticlePubMedGoogle Scholar
  59. Liu Y, Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Rich SS, Bowden DW, Freedman BI: T-786C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the diabetes heart study. J Am Soc Nephrol. 2005, 16: 1085-1090. 10.1681/ASN.2004100817.View ArticlePubMedGoogle Scholar
  60. Dell'Omo G, Penno G, Pucci L, Fotino C, Lucchesi D, Del Prato S, Pedrinelli R: Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men. J Hypertens. 2007, 25: 1389-1395. 10.1097/HJH.0b013e3281268548.View ArticlePubMedGoogle Scholar
  61. Hoffmann IS, Tavares-Mordwinkin R, Castejon AM, Alfieri AB, Cubeddu LX: Endothelial nitric oxide synthase polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics. J Hum Hypertens. 2005, 19: 233-240.PubMedGoogle Scholar
  62. Nath SD, He X, Voruganti VS, Blangero J, MacCluer JW, Comuzzie AG, Arar NH, Abboud HE, Thameem F: The 27-bp repeat polymorphism in intron 4 (27 bp-VNTR) of endothelial nitric oxide synthase (eNOS) gene is associated with albumin to creatinine ratio in Mexican Americans. Mol Cell Biochem. 2009, 331: 201-205. 10.1007/s11010-009-0159-5.View ArticlePubMedPubMed CentralGoogle Scholar
  63. Ichikawa K, Konta T, Emi M, Toriyama S, Takasaki S, Ikeda A, Shibata Y, Takabatake N, Takeishi Y, Kato T, et al: Genetic polymorphisms of paraoxonase-1 are associated with chronic kidney disease in Japanese women. Kidney Int. 2009, 76: 183-189. 10.1038/ki.2009.97.View ArticlePubMedGoogle Scholar
  64. Konta T, Emi M, Toriyama S, Ariumi H, Ishii M, Takasaki S, Ikeda A, Ichikawa K, Shibata Y, Takabatake N, et al: Association of CC chemokine ligand 5 genotype with urinary albumin excretion in the non-diabetic Japanese general population: the Takahata study. J Hum Genet. 2008, 53: 267-274. 10.1007/s10038-008-0246-6.View ArticlePubMedGoogle Scholar
  65. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E: Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes. 2002, 51: 2653-2657. 10.2337/diabetes.51.8.2653.View ArticlePubMedGoogle Scholar
  66. Hsu CC, Kao WH, Coresh J, Pankow JS, Marsh-Manzi J, Boerwinkle E, Bray MS: Apolipoprotein E and progression of chronic kidney disease. JAMA. 2005, 293: 2892-2899. 10.1001/jama.293.23.2892.View ArticlePubMedGoogle Scholar
  67. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A: Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes. 2004, 53: 1570-1576. 10.2337/diabetes.53.6.1570.View ArticlePubMedGoogle Scholar
  68. Kaunisto MA, Sjolind L, Sallinen R, Pettersson-Fernholm K, Saraheimo M, Frojdo S, Forsblom C, Fagerudd J, Hansen TK, Flyvbjerg A, et al: Elevated MBL concentrations are not an indication of association between the MBL2 gene and type 1 diabetes or diabetic nephropathy. Diabetes. 2009, 58: 1710-1714. 10.2337/db08-1495.View ArticlePubMedPubMed CentralGoogle Scholar
  69. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, Itoh Y, Lieske JC, Seccombe DW, Jones G, et al: Current issues in measurement and reporting of urinary albumin excretion. Clin Chem. 2009, 55: 24-38. 10.1373/clinchem.2008.106567.View ArticlePubMedGoogle Scholar
  70. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005, 67: 2089-2100. 10.1111/j.1523-1755.2005.00365.x.View ArticlePubMedGoogle Scholar
  71. Gansevoort RT, Verhave JC, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D, de Jong PE: The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl. 2005, S28-35. 10.1111/j.1523-1755.2005.09408.x.Google Scholar
  72. Gaspari F, Perico N, Remuzzi G: Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis. 2006, 47: 1-7. 10.1053/j.ajkd.2005.10.014.View ArticlePubMedGoogle Scholar
  73. Kramer HM, Hsu CY, Curhan G: Need for sex-specific ACR. Am J Kidney Dis. 2002, 40: 435-436. 10.1053/ajkd.2002.35117. author reply 437View ArticlePubMedGoogle Scholar
  74. Mattix HJ, Hsu CY, Shaykevich S, Curhan G: Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002, 13: 1034-1039.PubMedGoogle Scholar
  75. Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996, 7: 930-937.PubMedGoogle Scholar
  76. Knight EL, Curhan GC: Albuminuria: moving beyond traditional microalbuminuria cut-points. Curr Opin Nephrol Hypertens. 2003, 12: 283-284. 10.1097/00041552-200305000-00009.View ArticlePubMedGoogle Scholar
  77. Gonzalez JR, Carrasco JL, Dudbridge F, Armengol L, Estivill X, Moreno V: Maximizing association statistics over genetic models. Genet Epidemiol. 2008, 32: 246-254. 10.1002/gepi.20299.View ArticlePubMedGoogle Scholar
  78. Lettre G, Lange C, Hirschhorn JN: Genetic model testing and statistical power in population-based association studies of quantitative traits. Genet Epidemiol. 2007, 31: 358-362. 10.1002/gepi.20217.View ArticlePubMedGoogle Scholar
  79. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003, 41: 1-12. 10.1053/ajkd.2003.50007.View ArticlePubMedGoogle Scholar
  80. Krolewski AS, Poznik GD, Placha G, Canani L, Dunn J, Walker W, Smiles A, Krolewski B, Fogarty DG, Moczulski D, et al: A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Kidney Int. 2006, 69: 129-136. 10.1038/sj.ki.5000023.View ArticlePubMedGoogle Scholar
  81. Bamshad M: Genetic influences on health: does race matter?. JAMA. 2005, 294: 937-946. 10.1001/jama.294.8.937.View ArticlePubMedGoogle Scholar
  82. Bamshad M, Wooding S, Salisbury BA, Stephens JC: Deconstructing the relationship between genetics and race. Nat Rev Genet. 2004, 5: 598-609. 10.1038/nrg1401.View ArticlePubMedGoogle Scholar
  83. Sinha M, Larkin EK, Elston RC, Redline S: Self-reported race and genetic admixture. N Engl J Med. 2006, 354: 421-422. 10.1056/NEJMc052515.View ArticlePubMedGoogle Scholar
  84. Tang H, Quertermous T, Rodriguez B, Kardia SL, Zhu X, Brown A, Pankow JS, Province MA, Hunt SC, Boerwinkle E, et al: Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet. 2005, 76: 268-275. 10.1086/427888.View ArticlePubMedGoogle Scholar
  85. Yang N, Li H, Criswell LA, Gregersen PK, Alarcon-Riquelme ME, Kittles R, Shigeta R, Silva G, Patel PI, Belmont JW, Seldin MF: Examination of ancestry and ethnic affiliation using highly informative diallelic DNA markers: application to diverse and admixed populations and implications for clinical epidemiology and forensic medicine. Hum Genet. 2005, 118: 382-392. 10.1007/s00439-005-0012-1.View ArticlePubMedGoogle Scholar
  86. Houlihan CA, Tsalamandris C, Akdeniz A, Jerums G: Albumin to creatinine ratio: a screening test with limitations. Am J Kidney Dis. 2002, 39: 1183-1189. 10.1053/ajkd.2002.33388.View ArticlePubMedGoogle Scholar
  87. Verhave JC, Hillege HL, de Zeeuw D, de Jong PE: How to measure the prevalence of microalbuminuria in relation to age and gender?. Am J Kidney Dis. 2002, 40: 436-437. 10.1053/ajkd.2002.35118. author reply 437View ArticlePubMedGoogle Scholar
  88. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/11/155/prepub

Copyright

© Ned et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.